The MPS1/TTK inhibitor, NMS-01940153, synergizes with tisotumab vedotin in colorectal cancer
G. Texido, F. Gasparri, A. Ciavolella, L. Gianellini, A. Burocchi, I. Fraietta, A.E. Pedersen, A. Ocaña, R. Colombo, D. Roberti, L. Mahnke, C. Perrera AACR Annual Meeting 2024; April 5-10, 2024; San Diego –Abstract 509 Cancer Res (2024) 84 (6_Supplement)
Development of 14-amino-anthracyclines as novel payloads for ADC production showing potent anti-tumor activity and improved safety profile
P. Orsini, M. Salsa, A. Burocchi, A. Ciavolella, U. Cucchi, D. Faiardi, S. Rizzi, F. Gasparri, B. Valsasina 38th National Medicinal Chemistry Symposium; June 23-26, 2024; Seattle, WA.
A payload-linker generating machine to quickly move from small molecules to characterized tool ADCs and PDCs
R. Lupi, P. Orsini, M. Salsa, S. Rizzi, U. Cucchi, D. Faiardi, A. Burocchi, A. Ciavolella, F. Gasparri, B. Valsasina 14th World ADC London 2024; March 12-15, 2024; London, UK
Discovery of NMS-0963, a potent, selective and orally available Syk inhibitor with outstanding preclinical activity in diffuse large B-cell lymphoma
L. Buffa, G. Cervi, R. D’Alessio, S. Bindi, A. Burocchi, G. Canevari, M. Modugno, I. Motto, G. Saturno, P. Orsini 58th International Conference on Medicinal Chemistry (RICT 2024); July 3-5, 2024; Bordeaux, France
Photocatalytic Giese reaction of boron-containing compounds with α-Halogenated electron-poor olefins
M. Caldarelli, S.J. Rezzi, N. Colombo, T.Pirali, G. Papeo EFMC-ISMC 2024; XXVIII EFMC International Symposium on Medicinal Chemistry; September 1-5, 2024; Rome, Italy –Abstract P411
Nerviano Medical Sciences announces FDA protocol clearance of new IND application for NMS-812, a first-in-class dual inhibitor of PERK/GCN2. Brian Sherer, PhD. appointed to lead and accelerate the development.
NMS-812: A clinical phase potent and selective PERK/GCN2 inhibitor, a potential first-in-class targeting the integrated stress response (ISR) The United States Food and Drug Administration (FDA) has cleared the protocol for new investigational new drug (IND) application for NMS-812, a first-in-class orally bioavailable and highly potent small molecule dual inhibitor of PERK/GCN2. NMS […]
Nerviano Medical Sciences announces strategic portfolio shaping.
NERVIANO, IT and BOSTON, Mass, June 21 , 2024 – Nerviano Medical Sciences S.r.l. (“NMS” or the “Company”), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, […]
Nerviano Medical Sciences S.r.l. announced new Board of Directors and Statutory Auditors
NERVIANO, 28, May 2024_Nerviano Medical Sciences S.r.l. (NMS), a wholly owned subsidiary of NMS Group S.p.A, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced, following the shareholder resolution dated 13 May 2024, changes to the Board of Directors and Statutory Auditors of the holding company […]
Dr. Frank Narjes Appointed as Head of Medicinal Chemistry and Drug Design, Elevating Innovation at Nerviano Medical Sciences S.r.l.
NERVIANO, IT and BOSTON, Mass, May 13, 2024 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, welcomes Dr. Narjes to […]
Nerviano Medical Sciences S.r.l. presents data on MPS1 inhibitor NMS-153 and on ADC platform at the AACR annual meeting 2024.
Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud of its participation to the American Association of Cancer Research annual meeting (AACR 2024) which took place in San Diego from April 5th to April 10th. NMS […]